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ABSTRACT
Introduction: We describe a proactive method
using electronic patient records (EPR) to
identify pseudophakic patients with diabetic
macular oedema (DMO) that might benefit
from treatment with 0.2 lg/day fluocinolone
acetonide (FAc; ILUVIEN) implant.
Methods: Our EPR audit tool (Medisoft)
identified diabetic patients (May
2011–December 2014) with National Screening
Committee-confirmed grade M1 maculopathy.
Searches segmented this DMO patient
population into patient groups who: (1) had
received ranibizumab therapy, (2) had received
C2 macular laser treatments, or (3) were
unsuitable for macular laser or ranibizumab
therapy. Pre-specified criteria identified
patients insufficiently responsive to treatment,
and their electronic case notes were flagged for
clinicians to consider FAc, based on National
Institute for Health and Care Excellence (NICE)
TA301.
Results: Using this methodology, 138 patients
with DMO were identified, of whom 87 were
assigned to group 1, 32 to group 2, and 29 to
group 3 (10 patients were included in both
groups 2 and 3). From these, 28 different
pseudophakic eyes were identified as
suitable for treatment with FAc, based on
insufficient response to prior treatment.
Conclusion: EPR audit offers a real-world
methodology to efficiently identify patients
that might benefit from treatment with FAc.
Limitations apply, and thorough
documentation of lens status and ocular
comorbidities is vital; however, this approach
was more rapid than prospective recruitment
through the clinic. Flagging patient records
using EPR audit offers a practical process for
application to clinical practice, thereby
optimizing patient care in line with NICE
TA301 guidelines.
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INTRODUCTION
Diabetic retinopathy (DR) is a common,
vision-limiting vascular complication of
diabetes with a prevalence of approximately
35% [1, 2]. A visual complication manifesting in
6.8% of patients with DR is diabetic macular
oedema (DMO), a chronic condition and the
most common cause of DR-related vision-loss,
particularly in patients with type 2 diabetes [2,
3]. 14–25% of patients diagnosed with diabetes
appear to develop DMO within 10 years of the
initial diagnosis [4].
Given the association between DMO and
vision loss, its early and effective management
is critical. However, as a chronic and persistent
visual complication that does not follow the
natural disease course of DR, it is difficult to
manage [3]. Historically, the standard of care
was laser therapy, and this approach is still
widely used. More recently, the preferred
standard of care in patients with DMO has
become anti-VEGF therapy [5]. This approach is
supported by the outcomes from several large,
prospective, randomized clinical trials
demonstrating improvements in DMO and
associated visual function [6–8]. However, a
notable proportion of patients remain
insufficiently responsive to anti-VEGF
treatment in clinical practice, as shown by a
cohort of patients (n = 190) in the RIDE and
RISE trials (ClinicalTrials.gov identifiers:
NCT00473382 and NCT00473330,
respectively), who crossed over from sham to
ranibizumab treatment after two years. In this
patient group, the improvement in VA after
1 year of therapy was notably less when
compared with 1-year gain in VA in patients
who initiated ranibizumab at the start of the
study [mean 2.8 vs. 11.1 Early Treatment
Diabetic Retinopathy (ETDRS) letter gain,
respectively] [7, 8] suggesting that patients
with a longer duration of DMO (chronic
DMO) were less likely to achieve a response
with ranibizumab.
Diabetic macular oedema is a multifactorial
disease, involving the up-regulation of multiple
inflammatory cytokines in addition to VEGF
[9]. Consequently, corticosteroids, which have a
broader-spectrum of activity, may represent an
alternative therapeutic option for patients with
chronic DMO. Data from the Fluocinolone
Acetonide in Diabetic Macular Edema [FAME
(ClinicaTrials.gov identifier. NCT00344968)]
trials indicate efficacy of 0.2 lg/day FAc
implant in DMO [17]. In Europe, 0.2 lg/day
FAc implant is approved for the treatment of
vision impairment associated with chronic
DMO considered insufficiently responsive to
available therapies [10]. In the UK, the National
Institute for Health and Care Excellence (NICE;
TA301) recommends 0.2 lg/day FAc implant as
an option for treating chronic DMO that is
insufficiently responsive to available therapies
in eyes that are pseudophakic [11].
The timely implementation of NICE
technology appraisals (TAs) is an ethical
responsibility and an opportunity to enhance
patient care. National Health Service (NHS)
trusts have 3 months to implement guidance
and a proactive, methodical approach is needed
to optimise TA implementation. Medisoft
(Medisoft Ltd., Leeds, UK) is an electronic
patient records (EPR) database, which in our
practice contains the details for a large diabetic
patient population. Here, we report a
methodology that utilizes this EPR audit tool
to identify patients who may have sub-optimal
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responses to current first-line treatment options
(anti-VEGF or laser) and consequently, who
might benefit from 0.2 lg/day FAc implant.
This methodology can be approached from
different angles to optimally identify patient
groups that meet pre-specified criteria for
insufficient response or treatment failure. The
data presented within this manuscript are based
on searches using EPR records for patients
within the Calderdale and Huddersfield NHS
Foundation Trust, which serves a population of
approximately 22,500 patients with type 1 and
type 2 diabetes in Calderdale and South
Kirklees, UK. To our knowledge, no prior
studies have reported the use of EPR audit to
identify patients with DMO suitable for
subsequent therapy.
METHODS
Using the Medisoft EPR tool, searches spanning
May 2011–May 2014 were conducted using
pre-determined search terms (see the Appendix
in the supplementary material), tailored to
identify all patients referred to the Calderdale
and Huddersfield NHS Foundation Trust with
National ScreeningCommittee (NSC)-confirmed
grade M1 maculopathy [i.e., exudate within 1
disc diameter (DD) of the centre of the fovea,
circinate or group of exudateswithin themacula,
retinal thickening within 1DD of the centre of
the fovea (if stereo available) or any
microaneurysm or haemorrhage within 1DD of
the centre of the fovea only if associated with a
best visual acuity (VA) of B6/12 (if no stereo)].
Identified patients were further divided into 3
pre-specified patient groups that might include
patients who could benefit from 0.2 lg/day FAc
implant (Fig. 1). For each of these patient groups,
information on patient demographics and
disease history were gathered, as was
information relating to therapeutic
interventions, VA (ETDRS letter score) and
anatomical measures of DMO [e.g., central
retinal thickness (CRT) according to optical
coherence tomography (OCT) map, lm].
Patients who might benefit from 0.2 lg/day FAc
were identified in each of the 3 patient groups
(Fig. 1), based on the demographic and disease
characteristics, and the corresponding electronic
case notes were flagged as potentially suitable for
therapy with a note for the clinician to consider
0.2 lg/day FAc implant based on TA301. The
selection process and methodology for
identifying patients is outlined for each group
below. This article does not contain any new
studies with human or animal subjects
performed by any of the authors.
Group 1: Patients Insufficiently
Responsive to Ranibizumab
The EPR audit tool was used to identify patients
among those patients with NSC-confirmed
grade M1 maculopathy who had received
ranibizumab treatment (Fig. 1). Patient records
were exported for identified patients, excluding
any with non-DMO indications. For this
analysis, treatment success was evaluated in
eyes that had received C3 consecutive
ranibizumab injections. The selection of this
time point for the assessment of response is
supported by the results of the Early Anti-VEGF
Response and Long-term Efficacy (EARLY)
study, which showed that long-term response
to anti-VEGF therapy in patients with DMO
could be predicted after three injections
(ClinicaTrials.gov identifier. NCT00445003)
[12]. Patients with a baseline VA of[68 letters
were considered unresponsive to ranibizumab if
they achieved less than a 20% reduction in CRT
or a loss in VA of[5 letters. In patients who had
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a baseline VA of \68 letters, non-response to
ranibizumab treatment was defined as less than
20% reduction in CRT or a gain in VA of
\5 letters. The exported patient records were
reviewed to determine which pseudophakic
patients (to comply with NICE TA301) [11]
with DMO were insufficiently responsive to
ranibizumab based on these response criteria,
and their patient records flagged accordingly.
Group 2: Patients Unresponsive to Macular
Laser Therapy
The EPR audit tool was used to identify which
patients with NSC-confirmed grade M1
maculopathy had received more than one
macular laser treatment (Fig. 1, group 2). In
addition, those patients assigned to group 1
during the EPR search, having received
ranibizumab, were cross-checked and any
duplicate patient entries deleted; therefore, all
patients included in group 2 were ranibizumab
naı¨ve. Records for patients with non-DMO
indications were excluded.
The selected patient records were exported
and reviewed to identify pseudophakic patients
with DMO unresponsive to macular laser
therapy. Patients who had received more than
one laser treatment with persistent DMO (based
on clinical judgement of OCT maps and CRT
values [250 lm) were deemed to have failed
laser therapy.
Fig. 1 Schematic illustrating the three different patient groups identiﬁed using the Medisoft EPR tool. EPR electronic
patient records
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Group 3: Patients
Unsuitable for Ranibizumab or Macular
Laser Treatment
Those patients with NSC-confirmed grade M1
maculopathy who were originally identified and
who did not conform to the criteria specified for
inclusion in group 1 or 2were included in group 3
(excluding all patients with non-DMO
indications; Fig. 1). These patients had CRT
greater than 250 lm but less than 400 lm and so
were considered unsuitable for ranibizumab
treatment in the UK, based on NICE TA274
guidance (recommends ranibizumab only in
patients with CRT[400 lm) [13]. Consequently,
patient records were screened to identify those
patientswheremacular laser therapymightnotbe
optimal and anti-VEGF therapy is not
recommended, but who might benefit from
early intervention with 0.2 lg/day FAc implant
to reduce CRT and manage DMO progression
effectively. Of note, this patient group included
some patients who were unsuitable for laser or
ranibizumab therapy but who had received prior
laser therapy. Consequently, such patients who
had received two or more laser treatments were
‘counted twice’ as they were also included in
group 2.
RESULTS
Overall, the EPR search identified 138 patients
with DMO, whose demographic characteristics
were broadly as anticipated (Table S1 in the
supplementary material). The average patient
age was 64 years [range 27–86 years; standard
deviation (SD) ±13.1 years], and most patients
were male (n = 85). The majority of patients had
type 2 diabetes (n = 112). Of the 138 patients
(264 eyes), 67 eyes were pseudophakic, 123 were
phakic, and in the remaining 74 eyes the lens
status was not documented (Fig. 1).
Group 1: Patients Insufficiently
Responsive to Ranibizumab
Overall, 87 patients had received treatment
with ranibizumab and were allocated to group
1 (Table S1). Of the 87 patients, 26 eyes from
26 patients were pseudophakic and had
received C3 consecutive ranibizumab
injections.
At baseline, 16/26 patients had a
best-corrected (BC) VA of \68 letters, and 10
patients had a BCVA of[68 letters; mean BCVA
was 57.5 letters (range 24–75 years;
SD ±14.2 years). Baseline CRT ranged from 320
to 880 lm, with a mean CRT of 473.8 lm
(SD ±111.8 lm). Three eyes were excluded
from further analysis; 1 patient was awaiting
follow-up at the time of analysis and 1 had
concomitant wet age-related macular
degeneration (wAMD). The third patient was
not insufficiently responsive to ranibizumab
based on the defined study criteria; however,
they received 0.2 lg/day FAc implant based on
physician assessment.
Based on the pre-specified parameters for
insufficient response following ranibizumab
therapy, 13 eyes were determined to have
failed ranibizumab therapy and consequently
were considered suitable for 0.2 lg/day FAc
implant; in these eyes there was a mean
reduction in CRT of -110.3 lm
(SD ±142.8 lm) and a change in BCVA of
-5.7 letters (SD ±12.1 letters) from
pre-ranibizumab baseline was reported. In the
remaining 10/26 eyes, which were responding
to ranibizumab, a mean reduction in CRT of
-203.7 microns (SD ±99.2) and mean increase
in BCVA of 9.4 letters (SD ±10.6 letters) was
reported. Table 1 presents the data on prior
interventions as well as CRT and BCVA at
baseline and following ranibizumab therapy
for each eye.
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Group 2: Patients Unresponsive to Macular
Laser Therapy
Overall, 50 eyes from 32 patients were
ranibizumab naı¨ve and had received more
than 1 macular laser treatment, of which 13
were pseudophakic and a further 15 had
unknown lens status. The majority of patients
received more than 2 laser treatments and 5
eyes reported co-pathologies (Table 2). At the
time of analysis, the most recent CRT ranged
from 219 to 368 lm (mean 286.9 lm;
SD ±53.3 lm) and the most recent BCVA from
42 to 82 letters. The majority of patients
(n = 16) had a BCVA in line with driving
vision (70 letters) or better. Table 2 presents
the data on functional and anatomical visual
measurements for each eye.
Based on the pre-specified criteria, 10/13
pseudophakic eyes were deemed to have failed
macular laser therapy and thus were considered
potential candidates for 0.2 lg/day FAc implant.
In these patients, the mean change in
CRT and BCVA from baseline (referral) were
?8.2 lm (SD ±54.7 lm) and -13.1 letters
(SD ±11.1 letters), respectively. Patients with
unknown lens status were considered
unsuitable for 0.2 lg/day FAc implant at this
time, as their lens status was assumed to be
phakic.
Group 3: Patients with Centre-Involving
DMO Unsuitable for Ranibizumab
or Macular Laser Treatment
Overall, 40 eyes from 29 patients were allocated
to group 3 (Table S1). In those patients (n = 23)
who were pseudophakic or with unknown lens
status, 11 eyes had previously received 1–3 laser
treatments and 3 eyes reported co-pathologies
(Table 3). BCVA at referral ranged from 50 to
90 letters (mean 78.4 letters; SD ±12.0 letters),
and appeared relatively stable with a mean
recent BCVA at the time of analysis of
74.3 letters (range 54–90 letters;
SD ±8.1 letters). CRT was \400 lm in all
patients and ranged from 228 to 345 lm
(mean 297.2 lm; SD ±31.1 lm). Of the 23
eyes, 5 pseudophakic eyes were selected as
suitable candidates for 0.2 lg/day FAc implant
[eye 4 was also counted in group 2 (eye 1)]. All 5
patients had good VA (mean 72.0 letters;
SD ±12.7 letters) and CRT [250 lm (mean
303.0 lm; SD ±28.5 letters). Patients with
unknown lens status were considered
unsuitable for 0.2 lg/day FAc implant at this
time, as their lens status was assumed to be
phakic.
DISCUSSION
In this study, we used a simple, EPR-based
methodology to identify patients insufficiently
responsive to their current treatments and
consequently potential candidates for
0.2 lg/day FAc implant. Using the defined
search criteria, 13 pseudophakic eyes from 87
patients were identified as unresponsive to
ranibizumab and potentially suitable for
0.2 lg/day FAc implant (and have
subsequently been treated). Similarly, of the
pseudophakic eyes identified in groups 2 and 3,
10 and 5 eyes, respectively, were considered
potential candidates for 0.2 lg/day FAc implant.
Of these, 7 and 2 patients, respectively, have
received a 0.2 lg/day FAc implant.
NICE TA301 criteria state that pseudophakic
patients with DMO can be treated with
0.2 lg/day FAc implant where other standard
therapies have shown an insufficient response
[11]. To identify appropriate patients who are
insufficiently responsive and who might benefit
from this treatment, a practical approach with
broad applicability is required. This study
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demonstrates the utility of an EPR audit tool to
identify appropriate patients, based on
pre-defined search criteria. Different search
criteria were applied, allowing the
identification of patients who were either
insufficiently responsive, or unsuitable for
conventional treatments. The time required to
identify patients with this approach was in the
Table 3 Prior therapeutic interventions, CRT, and BCVA in patients with centre-involving diabetic macular oedema who














1 Pseudophakic Pallor of optic disc None 266 73 75 N
2 Pseudophakic None 279 70 70 Y
3 Pseudophakic None 293 60 70 Y
4 Pseudophakic 92 laser 325 90 70 Y
5 Pseudophakic None 265 90 75 Y
6 Pseudophakic BRVO, CRVO 92 laser 342 70 61 N
7 Pseudophakic Corneal scar 91 laser 324 50 54 N
8 Pseudophakic None 326 70 75 Y
9 Pseudophakic None 307 75 75 N
10 UNK 92 laser 228 60 75 N#
11 UNK 93 laser 290 85 70 N#
12 UNK 92 laser 264 85 75 N#
13 UNK None 328 75 75 N#
14 UNK None NN 90 NN N#
15 UNK None 300 85 85 N#
16 UNK 91 laser 285 90 70 N#
17 UNK 91 laser 310 75 NN N#
18 UNK 92 laser 277 90 75 N#
19 UNK None 345 90 85 N#
20 UNK None 306 85 85 N#
21 UNK None 273 90 90 N#
22 UNK 93 laser 265 90 80 N#
23 UNK 91 laser 341 66 70 N#
Mean (±SD) in pseudophakic patients 303.0
(28.5)
72.0 (12.7) 69.4 (7.4) N = 9
Overall mean (±SD) 297.2
(31.1)
78.4 (12.0) 74.3 (8.1) N = 23
BCVA best-corrected visual acuity, BRVO branch retinal vein occlusion, CRT central retinal thickness, CRVO central retinal vein
occlusion, FAc ﬂuocinolone acetonide, N no, SD standard deviation, UNK unknown. NN, no number
a Some patients were considered unsuitable for 0.2 lg/day FAc implant based on physician assessment and disease history (e.g., patients
with a history of glaucoma/raised intra-ocular pressure were deemed unsuitable for 0.2 lg/day FAc implant)
b UNK patients are considered unsuitable for 0.2 lg/day FAc implant, as they are assumed to be phakic (recent cataract surgeries are
recorded on Medisoft)
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order of a few days, compared with the long
process (months) of prospective identification
through the clinic.
The anti-VEGF injection, ranibizumab,
reaches therapeutic stability following treatment
initiation with 3 consecutivemonthly injections;
after this time, the majority of potential visual
gain has been achieved [14, 15]. Consequently,
for patients treated with ranibizumab in this
study, success was evaluated in patients who had
received C3 consecutive ranibizumab injections.
The criteria for treatment success were defined as
a function of baseline VA. In patients with good
baseline vision (C68 letters), but anatomical
evidence for vision-threatening DMO (e.g.,
CRT C400 lm), the aim of treatment was to
improve DMO (C20% reduction in CRT) or a
gain of vision ([5 letters). However, in patients
with worse vision (\68 letters), the aim of
treatment was considered to be an improvement
in DMO or maintenance of visual function
(\5 letter gain). It is arguably of particular
importance to identify treatment failure early in
this latter group, as a retrospective analysis of the
FAME studies demonstrated that visual outcomes
were better in patients with chronic DMO with
less deterioration in baseline BCVA whether they
were treated with intermittent therapies or
0.2 lg/day FAc implant; however, patients in
the latter group achieved notably better
outcomes [16].
A potentially overlooked cohort is those
patients with DMO who have a CRT\400 lm.
It is assumed that, as they cannot access
ranibizumab therapy in the UK due to a lack
of evidence for cost-effectiveness in this patient
group [13], they will be treated with macular
laser therapy. However, a proportion of patients
exist for whom laser therapy would be
potentially damaging, for example if the laser
needs to be applied close to the centre of the
retina. In addition, patients may have CRT
\400 lm, but have received prior laser therapy
that had been unsuccessful. This group of
patients has a need for effective intervention
to optimise outcomes and limit the damaging
effects of progressive DMO, and thus represent a
subgroup that may benefit from 0.2 lg/day FAc
implant. Here, patients with CRT\400 lm but
[250 lm who were not suitable for laser or
ranibizumab therapy were reviewed to consider
their suitability for 0.2 lg/day FAc implant,
identifying a further 5 pseudophakic eyes
whose records were flagged accordingly.
In this study, we have shown the potential
to use the EPR audit tool effectively,
proactively, and rapidly to identify patients
who are insufficiently responsive or failing to
respond to current standard-of-care
treatments. In addition, we propose a
practical mechanism for the clinical
application of this methodology through the
flagging of individual patient records. This
approach allows the efficient and timely
identification of patients who might benefit
from 0.2 lg/day FAc implant, which has both
ethical and socioeconomic implications.
Earlier, effective treatment has the potential
for improved visual outcomes and subsequent
quality of life, which in turn affects the
patients’ ability to work and the frequency
of treatment visits required. While the current
study has illustrated that there may be a
therapeutic solution for pseudophakic
patients with insufficient response to their
current therapy, there remains a significant
gap in care options for phakic patients that is
not currently addressed. Additionally, this
retrospective approach could highlight a
number of other patient groups that are not
being effectively treated, and for whom there
is a question of optimal management.
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Limitations
There are several important considerations and
potential limitations to consider. Complete
documentation of current lens status and the
presence of ocular comorbidities is necessary for
the effective identification of suitable patients,
and whilst paper and EPR systems are in
concurrent use, it is likely that neither record
will be complete. However, in the UK there is a
paperless initiative in place, which mandates
that all patient records should be fully digital by
April 2018, with a clear move towards a
paper-light system by 2015 [17]. This will
require complete digital documentation, both
facilitating and enhancing the value of an EPR
audit system such as that described here.
However, more extensive digital patient
records will not obviate the need for
appropriate consideration of optimal search
terms. Additionally, this study was performed
within the context of the UK healthcare system
using a specific EPR tool. However, the
objectives of the study are relevant to other
healthcare systems and the methodology is
likely to be transferable to other technology
platforms; the flexibility of EPR tools allows the
use of locally derived criteria for the selection of
specific patient populations.
CONCLUSIONS
To conclude, EPR audit offers a real-world and
readily applicable methodology for optimizing
treatment options in patients with DMO.
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